Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 11/20 | 0.73 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370695 | 0.89 | AGPAT2 (0.71) | AGPAT2PDE4BPDE4D | |
| SCHEMBL13622466 | 0.88 | AGPAT2 (0.56) | AGPAT2CDK9PDE4BPDE4D | |
| SCHEMBL29406206 | 0.84 | AGPAT2 (1.00) | AGPAT2CDK9PDE4D | |
| SCHEMBL13622457 | 0.84 | AGPAT2 (1.00) | AGPAT2CDK9PDE4D | |
| SCHEMBL4362302 | 0.84 | AGPAT2 (0.77) | AGPAT2CDK9PDE4B | |
| SCHEMBL4373020 | 0.84 | AGPAT2 (0.77) | AGPAT2CDK9 | |
| SCHEMBL16705051 | 0.81 | AGPAT2 (0.72) | AGPAT2CDK9 | |
| SCHEMBL4363411 | 0.80 | AGPAT2 (0.71) | AGPAT2CDK9 | |
| SCHEMBL4359673 | 0.80 | AGPAT2 (0.71) | AGPAT2CDK9 | |
| SCHEMBL13622467 | 0.79 | AGPAT2 (0.69) | AGPAT2CDK9PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | claimed |
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003037346-A1 | 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 39/4885CDK9 2263/4885PDE4B 1834/4885 |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 35/4885CDK9 2316/4885PDE4B 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.